Nuvation Bio Inc. Class A Common Stock (NUVB)

This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.

Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.

Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.

Nuvation Bio (NUVB) Q1 2026 Earnings Transcript

This oncology-focused biotech, advancing multiple clinical-stage therapeutics, just reported a notable insider sale in recent filings.

SSR Mining runs a diversified portfolio of gold, silver, and base metal mines across four continents with a vertically integrated model.

This clinical-stage biotech advances oncology therapies with a pipeline of novel small molecule inhibitors for hard-to-treat cancers.

Nuvation Bio (NUVB) Q4 2025 Earnings Transcript

Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025 earnings report. The biopharmaceutical company not only significantly surpassed revenue forecasts but also celebrated the highly successful commercial launch of

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

The bulls are lining up on Wall Street for this up-and-coming biotech stock.